Iterum Therapeutics plc (ITRM) Price Targets From Analysts
The tables below show price targets and recommendations from analysts covering Iterum Therapeutics plc.
|Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
The Trend in the Analyst Price Target
Over the past 7 days, ITRM's average price target has gone up $0.25.
ITRM Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The points below can provide you with additional insight regarding what the price target and recommendations metrics in the table above mean for investors.
- Iterum Therapeutics plc's average analyst price target is greater than 1.29% of all US stocks.
- ITRM has a greater upside potential (average analyst target price relative to current price) than 8.02% of Pharmaceutical Products stocks.
- Iterum Therapeutics plc's variance in analysts' estimates is less than 11.64% of stocks in the micro market cap category.
- The number of analysts covering the stock of ITRM is higher than 13.67% of Pharmaceutical Products stocks.
- The NA of ITRM is higher than practically none of all US stocks.
In the Pharmaceutical Products industry, PRLD, LCI and PAHC are the three stocks most similar to Iterum Therapeutics plc regarding the price target and analyst recommendation information presented here.
Is ITRM a Buy, Hold or Sell? See the POWR Ratings now!